Mainz, March 2018 – On March 15th, Prof. Dietmar Zehn from the Technical University of Munich, School of Life Sciences Weihenstephan, will be visiting Mainz in the context of our Seminars in Translational Oncology series (SITO). You are cordially invited to his talk at 5 pm in building 708 of the University Medicine Mainz. The
Mainz, February 16, 2018 – The Keystone Symposium on Antibodies as Drugs: Translating Molecules into Treatments, will take place February 25th – March 1st, 2018 at the Whistler Conference Centre in Whistler, Canada. Ugur Sahin will speak in the session on Novel Ways to Deliver Antibody Therapy on Thursday, March 1. The title of his lecture
We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced
In the course of evolution, the immune system has developed sophisticated mechanisms to identify and eliminate invading pathogens and degenerate cells, thereby preventing infection and tumor occurrence. When these mechanisms are ineffective or somehow bypassed, tumors or chronic infections may form. Clarifying the processes leading to ineffective immune defense is the central goal of the
Mainz, 2017-10-25 – TRON scientific advisor Prof. Dr. Dr. Cornelis J. Melief, Leiden, Netherlands, will be awarded with the degree of an honorary medical doctor. Melief will be awarded for his lifetime achievements as a pioneer of tumor immunology, as well as for his commitment and deserts regarding immunological research in Mainz. Further information about
Was versprechen neuartige personalisierte Krebsimmuntherapien? Wie können Patienten von Ihnen profitieren, und welche Risiken bergen die Behandlungen? Zwei neue Ansätze in der Krebsimmuntherapie sind die CAR-T-Methode und die so genannten Neoantigen-Vakzine. Beide werden gerade getestet und sind sehr vielversprechend. Der regionale Radiosender SWR2 sendete hierzu einen Radiobeitrag in seinem Programm. Einen Mitschnitt sowie ein Transkript
The 12th Mainz Clinical Pathology Seminar will assemble experts from the basic scientific, clinical, biopharmaceutical and pathological fields to give an overview of the exciting developments in cancer immunotherapies.
Among nucleic acid-based delivery platforms, self-amplifying RNA (saRNA) vectors are of increasing interest for applications such as transient expression of recombinant proteins and vaccination. Although saRNA is a promising technology, antigen expression from saRNA is limited by the host cells’ innate interferon response. TRON’s Tim Beissert and colleagues show, in an upcoming issue of Human
Mainz, June 2017 – We are pleased to announce that our close cooperation partner BioNTech has today published an article in Nature Medicine. The paper entitled “Elimination of large tumors in mice by mRNA-encoded bispecific antibodies” reports preclinical data featuring their novel class of mRNA-encoded antibody drugs called RiboMABs® and describes the application of their
Mainz, 20. December 2016 – TRON scientists kick off special issue in Frontiers in Immunology. This is a call for papers to provide an up-to-date overview of current efforts to understand the immunological mechanisms of neoantigen directed T-cell immunity and the attempts to harvest this source of antigens for cancer immunotherapy. Read more about the
Mainz, 23. November 2016 – Wie entstehen Krebszellen? Ist Krebs erblich? Warum ist es so schwer, Krebs zu behandeln/zu heilen und welche neuen Ansätze zur Krebsbehandlung gibt es? Welche Rolle spielt dabei die individualisierte Immuntherapie – und was ist das überhaupt? TRON und BioNTech tragen 11 Fakten über Krebs zu “Wissen im Herzen” bei, eine
Mainz, November 17 – ‘The immune biology of microsatellite instability cancer: Towards a vaccine against HNPCC’, Prof. von Knebel Doeberitz from the Institute of Pathology at the University of Heidelberg will speak in our seminar on Thursday during his visit at TRON.